(-0.06%) 5 475.00 points
(-0.11%) 38 776 points
(-0.02%) 19 917 points
(0.20%) $80.49
(1.22%) $2.82
(0.25%) $2 334.90
(-0.12%) $29.36
(-0.21%) $968.90
(0.01%) $0.932
(-0.14%) $10.64
(0.06%) $0.788
(-1.87%) $86.79
Live Chart Being Loaded With Signals
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions...
Stats | |
---|---|
Šios dienos apimtis | 1.28M |
Vidutinė apimtis | 971 825 |
Rinkos kapitalizacija | 12.60B |
EPS | $-3.01 ( Q4 | 2024-02-22 ) |
Kita pelno data | ( $0 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-28.09 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $4.03 (1.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Wheadon David E. | Sell | 990 | Common Stock |
2024-03-18 | Wheadon David E. | Sell | 25 000 | Option (right to buy) |
2024-03-18 | Wheadon David E. | Sell | 8 500 | Option (right to buy) |
2024-03-18 | Wheadon David E. | Sell | 5 000 | Option (right to buy) |
2024-03-18 | Wheadon David E. | Sell | 1 904 | Option (right to buy) |
INSIDER POWER |
---|
-93.84 |
Last 100 transactions |
Buy: 115 486 | Sell: 3 548 924 |
Tūris Koreliacija
Karuna Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
SPLK | 0.842 |
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Karuna Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Karuna Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $654 000 |
Bruto pelnas: | $-1.05M (-160.09 %) |
EPS: | $-11.73 |
FY | 2023 |
Pajamos: | $654 000 |
Bruto pelnas: | $-1.05M (-160.09 %) |
EPS: | $-11.73 |
FY | 2022 |
Pajamos: | $10.64M |
Bruto pelnas: | $9.53M (89.55 %) |
EPS: | $-8.74 |
FY | 2021 |
Pajamos: | $36.96M |
Bruto pelnas: | $36.96M (100.00 %) |
EPS: | $-5.44 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Karuna Therapeutics Inc
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.